New study finds CagriSema reduces food cravings
Novo Nordisk's cagrilintide-semaglutide combination showed effects on craving measures in newly reported data.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 1 02:24 ETSource: medwatch.com
The wire
- 01MedWatch reports a new study showing CagriSema, Novo Nordisk's amylin analog plus semaglutide combination, curbs food cravings.
- 02Craving and appetite endpoints matter for clinicians judging how amylin-incretin combinations differ from semaglutide alone in maintenance and adherence.
- 03Details on study size, design and duration were not laid out in the item; readers should await the full publication before drawing conclusions.
From the source
Read at medwatch.comCagriSema curbs food cravings, shows new study
